Katia Scotlandi graduated in Biological Sciences at University of Bologna, Italy, in 1986 and devoted her career to oncology research. Starting from specialization at the University of Bologna, she continued her training at the academic Rizzoli Institute, the main Italian center for bone sarcomas. She worked as visiting scientist at the University of Illinois, Chicago (1996), Kimmel Cancer Center in Philadelphia (1999), INSERM in Nice (2001) and University of Valencia (2009).
She is currently Acting Director of the SC Laboratory of Experimental Oncology, co-Director of the Oncology Research Line and member of the Management Board at the Rizzoli Institute, Bologna, Italy. She is also Secretary of the Working Group Sarcoma for Italian Alliance against Cancer (2016-present) and Adjunct Professor of Molecular Biology (2001-present) and she has mentoring for more than 70 students. She obtained the National Scientific Qualification for Full Professor in Applied Biology (05/F1); General and Clinical Pathology (06/A2); Molecular Biology (05/E2); Full Professor in Sciences of Health Professions and Applied Medical Technologies (06/N1).
From 2017, she is member of the Italian Top Women Scientists Committee. She served as President of the Italian Association of Cell Cultures from 2015-2018.
As reviewer, she is member of the Member of the Scientific Evaluation Committee of AIRC-FIRC Fellowships (2011-present) and of the International Translational/Clinical Cancer Research for French Ministry of Health and French National Cancer Institute-INCa (2011-present).
Her research is focused on discovering the players that control the malignancy of bone sarcomas, to define biomarkers of risk and best molecular therapeutic targets.
She awarded the Oswald Van der Veken Prize, Bruxelles (2011) and the Tina Anselmi Award, Bologna (2019).
She co-authored 200 papers in international peer-review journals (H-index: 48, Scopus) and filed 3 patents (one recognized in Europe, USA and Canada and licenced to a private company).
Link to Pubmed publications: https://www-ncbi-nlm-nih-gov.ezproxy.unibo.it/pubmed/?term=scotlandi
Link to ORCID: https://orcid.org/0000-0001-6114-9499
Link to the Research Group Website:
http://www.ior.it/laboratori/lab-di-oncol-sperim/laboratorio-di-oncologia-sperimentale
https://www.alleanzacontroilcancro.it/working-group/wg-sarcoma/
Major
titles:
1986: Graduated
in Biological Science with honor
1994: Staff
member of the Italian National Health System, specialized in
Clinical Pathology
2001: Director
of the Unit - Growth factor and receptors
2001-today:
Adjunct Professor at the University of
Bologna
2007-today:
Member of the Scientific Board of the International CCN
Society
2009-2013/2017-today:
Member of the Scientific Board of the Italian Society of
Cancer
2010-2013:
Vice-President of the Italian Association for Cell Cultures
(AICC)
2011-today:
Member of the Scientific Committee for Fellowships evaluation (CSB)
of the Italian Association/Foundation for Cancer Research
(AIRC-FIRC)
2011-2014 and from 2018:
Member of the Scientific Evaluation Committee for projects in
Translational Cancer Research for French Ministry of Health and
French National Cancer Institute (INCa) and President in June
and November 2014
2012: Evaluation
of research projects (VQR 2004-2010) on behalf of ANVUR (Evaluation
National Agency of the University System and Research)
2012: National
Scientific Qualification (Ministry of Education, University and
Research) as Associate Professor in Molecular Biology (05/E2),
Applied Biology (05/F1), Histology (05/H2), General and Clinical
Pathology (06/A2); Sciences of
Health Professionsand Applied Medical
Technologies (06/N1).
As full
Professor in Applied Biology (05/F1), General and Clinical
Pathology (06/A2)
2013: National Scientific Qualification (Ministry of Education, University and Research) asfull Professor in Molecular Biology (05/E2)
2015: Member of the Scientific Evaluation Committe of HCERES (High Council for Evaluation of Research and Higher Education)
2015-2017: Member of the Scientific
Evaluation Committee for projects for the International Clinical
Cancer Research (CIR2C), French National Cancer Institute (INCa),
France
2019-2021: Acting Director of the SC Laboratory of Experimental Oncology
2021-today: Chief of the SSD -Laboratory of Experimental Oncology
